Explore the most recent clinical developments in graft-versus-host disease (GVHD). Cancer Nursing Today provides up-to-date coverage of biomarkers for GVHD, chronic GVHD flares during immunosuppressive therapy, and more. From disease prevention in pediatric patients to drug evaluation for chronic GVHD, learn more about the evolution of GVHD care and research.
According to a recent study in The Lancet Haematology, individualized dosing of anti-thymocyte globulin yielded significant improvements in early CD4+ T-cell immune reconstitution in pediatric hematopoietic stem cell transplantation (HSCT) recipients—without increasing the incidences of graft-versus-host disease (GVHD) and graft failure. The phase 2 trial, led by Rick Admiraal, MD, enrolled 58 pediatric patients between July 1, 2015 and August 22, 2018 at the University Medical Center Utrecht and the Princess Máxima Center for Pediatric Oncology. Anti-thymocyte globulin dosing was based on patients’ bodyweight, initial absolute lymphocyte count, and graft source—ranging from ...
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...